Related Experiment Videos
Combating opportunistic infections: coccidioidomycosis
1University of Arizona, Southern Arizona Veterans Affairs Medical Center, Tucson, AZ 85723, USA. nampel@u.arizona.edu
Expert Opinion on Pharmacotherapy
|March 5, 2004
Summary
Coccidioidomycosis, a fungal infection, is increasing in the southwestern US, particularly affecting immunocompromised individuals. Treatment depends on severity, with triazoles and Amphotericin B being key antifungal therapies.
Area of Science:
- Mycology
- Infectious Diseases
- Immunology
Background:
- Coccidioidomycosis is a significant and growing public health concern in the southwestern United States.
- While healthy individuals can develop symptomatic disease, those with compromised cellular immunity face heightened risks.
Purpose of the Study:
- To review the epidemiology, risk factors, and current therapeutic strategies for coccidioidomycosis.
- To highlight the challenges in prevention and potential future interventions.
Main Methods:
- Literature review of coccidioidomycosis epidemiology and treatment guidelines.
- Analysis of risk factors, including HIV infection, transplantation, and immunosuppressive medications.
- Evaluation of antifungal treatment efficacy and resistance patterns.
Main Results:
- Disseminated coccidioidomycosis invariably requires antifungal therapy, unlike most primary pulmonary cases.
- Triazoles (fluconazole, itraconazole) are effective for most cases; Amphotericin B is reserved for severe or refractory infections.
- Coccidioidal meningitis necessitates lifelong triazole therapy, potentially with intrathecal Amphotericin B for treatment failures.
Conclusions:
- Effective management of coccidioidomycosis relies on risk stratification and appropriate antifungal selection.
- Environmental control for prevention is challenging; future strategies may involve immunization or immune modulation.
- Ongoing research is crucial for improved prevention and treatment of this emerging fungal pathogen.